Advertisement Effect of MAO-A Inhibition on the Pharmacokinetics of Almotriptan, an Antimigraine Agent in Humans - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Whitepapers

Effect of MAO-A Inhibition on the Pharmacokinetics of Almotriptan, an Antimigraine Agent in Humans

A study assessing the effect of a reversible MAO-A Inhibitor, moclobemide, on the singel-dose pharmacokinetices of almotriptan and assess the clinical consequences of any interaction.

Download whitepaper

Enter your details to get your free whitepaper:


Submit

I have read and accept the terms and conditions and privacy policy.

receive-email We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.

third-party If you would like to hear from carefully selected third party companies, check this box.

company-follow Follow this company to receive notifications when they update.


More from